Crescent Pharma Limited
Last updated Jun 24, 2026
Evidence Sources
3
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
78%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Cardiovascular
- ACE Inhibitor
- Psychiatry
- Antidepressant
Highest priority development: Pharmathen International S.A. - 723680 - 05/27/2026
Regulatory precedent
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Crescent Pharma Limited.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 78%
Active Signals
2
Investigate Priority
0
Opportunity Score
44
Buyer Quality
7 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 24, 2026Score 23Crescent Pharma recalls Ramipril 5mg capsules due to manufacturing error
Cardiovascular · ACE Inhibitor
- MonitorJun 23, 2026Score 21Cadila Pharmaceuticals Issues Class 4 Defect Notification for Mirtazapine 30mg Tablets
Psychiatry · Antidepressant
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- Pharmathen International S.A. - 723680 - 05/27/2026Moderate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and AnswersModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)Moderate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived PharmaceuticalsModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Crescent Pharma Limited right now?
- Which regulatory precedents should Crescent Pharma Limited monitor in Cardiovascular and ACE Inhibitor?
- Which pipeline programs should Crescent Pharma Limited prioritize for competitive review?
- What signals require immediate investigation for Crescent Pharma Limited?
- Summarize the strategic implications of recent developments for Crescent Pharma Limited.
- Where is the greatest uncertainty in Crescent Pharma Limited's competitive positioning?